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Diabetics have a higher incidence of urinary tract infection (UTI), are infected with a broader range of uro-
pathogens, andmore commonly develop serious UTI sequelae than nondiabetics. To better study UTI in the diabetic
host, we created and characterized a murine model of diabetic UTI using the pancreatic islet -cell toxin strepto-
zocin in C3H/HeN, C3H/HeJ, and C57BL/6 mouse backgrounds. Intraperitoneal injections of streptozocin were
used to initiate diabetes in healthy mouse backgrounds, as defined by consecutive blood glucose levels of >250
mg/dl. UTIs caused by uropathogenic Escherichia coli (UTI89), Klebsiella pneumoniae (TOP52 1721), and Enterococ-
cus faecalis (0852) were studied, and diabetic mice were found to be considerably more susceptible to infection. All
three uropathogens produced significantly higher bladder and kidney titers than buffer-treated controls. Uropatho-
gens did not have as large an advantage in the Toll-like receptor 4-defective C3H/HeJ diabetic mouse, arguing that
the dramatic increase in colonization seen in C3H/HeN diabetic mice may partially be due to diabetic-induced
defects in innate immunity. Competition experiments demonstrated that E. coli had a significant advantage over K.
pneumoniae in the bladders of healthy mice and less of an advantage in diabetic bladders. In the kidneys, K.
pneumoniae outcompeted E. coli in healthy mice but in diabetic mice E. coli outcompeted K. pneumoniae and caused
severe pyelonephritis. Diabetic kidneys contained renal tubules laden with communities of E. coli UTI89 bacteria
within an extracellular-matrix material. Diabetic mice also had glucosuria, which may enhance bacterial replication
in the urinary tract. These data support that this murine diabetic UTI model is consistent with known character-
istics of human diabetic UTI and can provide a powerful tool for dissecting this infection in themultifactorial setting
of diabetes.
Urinary tract infections (UTIs), which include infections of the
bladder (cystitis) and kidney (pyelonephritis), affect primarily
women and are responsible for nearly 13 million annual office
visits in the United States (16). One-third of women will experi-
ence a recurrent infection within 3 to 6 months of the initial
episode (19), and 44% will experience a recurrence within 1 year
(21). These infections are most commonly caused by the gram-
negative bacterium Escherichia coli, which is responsible for 80 to
85% of community-acquired UTIs; however, there are numerous
other pathogens capable of infecting the urinary tract (20, 47).
Uropathogenic E. coli (UPEC) employs a wide array of virulence
factors to successfully colonize and survive within the urinary
tract, including adhesive organelles, such as type 1, P, F1C, and S
pili (2, 22, 40, 41); iron acquisition/transport systems (51); hemo-
lysin (39); and flagella (27, 53). It has recently been found that
UPEC has the ability to invade bladder urothelial cells and rep-
licate to form intracellular bacterial communities largely pro-
tected from host innate immunity (1, 9, 23, 48). Bacteria disperse
from these intracellular bacterial communities, some in filamen-
tous morphology, which subverts elimination by polymorphonu-
clear leukocytes (PMN) and allows for further dissemination
throughout the urinary tract (24, 48).
Diabetes mellitus is the most common endocrine disease,
and worldwide incidence of this ailment is increasing (38).
Type 1 diabetes is an autoimmune disorder by which insulin-
producing islet  cells are destroyed by one’s own immune
system (15). Patients with type 1 diabetes, even with proper
management and glycemic control, can develop a variety of
diabetic sequelae, including retinopathy, neuropathy, nephrop-
athy, and numerous cardiovascular complications. Addition-
ally, diabetics are more prone to infection and these infections
are more severe than in nondiabetics (6, 44).
The urinary tract is the most common site of infection in the
diabetic host (30). Diabetics are more likely to have asymptomatic
and symptomatic bacteriuria (14, 42). Acute pyelonephritis is
approximately 10 times more common in the diabetic population
(37). In addition to a higher risk of developing UTI, diabetic
women have an increased risk of developing complications of
UTI, such as emphysematous cystitis, abscess formation, and re-
nal papillary necrosis (42). Although UPEC remains the predom-
inant etiologic agent of UTI in diabetic individuals, infections by
Klebsiella species (17, 29), enterococci (5, 29), Acinetobacter spe-
cies (36), group B streptococci (35), fungi (26), and other less
common uropathogens are more prevalent in diabetic women.
Many hypotheses have been attributed to the increase of UTI in
diabetic women, such as glucosuria, impaired immune cell func-
tion, or functional abnormalities of the urinary tract; however,
these theories have not been fully tested or confirmed in an
animal model of UTI (43). While there are multiple murine
models of diabetes, including the model of nonobese diabetic
mice (31), few have been used to effectively investigate diabetic
UTI. This study presents a streptozocin (STZ)-induced murine
model of diabetic UTI. This model is consistent with epidemio-
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logic observations of diabetic UTI and thus will greatly assist in
understanding the physiological and molecular mechanisms un-
derlying uropathogenesis in the diabetic setting. Using this model,
we discovered that diabetic mice are more prone to UTI and that
differences in virulence observed in the kidney and bladder are
dependent on the bacterial strain and host background.
MATERIALS AND METHODS
Bacterial strains and growth conditions. Clinical strains used in this study
were UTI89, a UPEC cystitis isolate (34); UTI89 hk::comGFP, a kanamycin-
resistant and green fluorescent protein-expressing strain of UTI89 (53); TOP52
1721 (abbreviated TOP52), a Klebsiella pneumoniae cystitis isolate (49); and
0852, an Enterococcus faecalis UTI isolate (25). Bacteria were cultured at 37°C in
Luria-Bertani (LB) broth (UTI89 and TOP52) or brain heart infusion broth
(0852). UTI89 hk::comGFP growth media also contained 50 g/ml kanamycin.
Induction of diabetes in mice. To develop a diabetic mouse model of UTI, we
gave 4- to 5-week-old female C3H/HeN (National Cancer Institute), C3H/HeJ
(Jackson Laboratories), or C57BL/6 (Jackson Laboratories) mice two to three
intraperitoneal (i.p.) injections of STZ (Sigma-Aldrich) to induce pancreatic islet
-cell death. Mice were weighed prior to injections, and STZ was freshly dis-
solved in dilution buffer (0.1 M sodium citrate, pH 4.5, with HCl, stored at 4°C)
and filter sterilized. To induce diabetes, mice were given 0.1-ml i.p. injections of
200 mg STZ/kg of body weight by use of a Precision Sure-Dose 1/2-ml3 syringe
with a 30-gauge, 3/8-in. needle. Dilution buffer-injected mice were used as
healthy controls. All mice were fed a normal diet. Blood glucose levels were
measured daily beginning 5 days after the second i.p. injection. STZ-injected
mice with glucose levels of 250 were given a third STZ i.p. injection. This
method consistently resulted in 80 to 85% penetrance of diabetes in STZ-
injected mice. Blood glucose levels were measured for each mouse, and a mouse
was considered diabetic after two consecutive readings of 250 mg/dl blood
glucose.
Mouse infections, competitions, and organ titers. Eight-week-old female dia-
betic or healthy control mice were infected by transurethral catheterization as
previously described (33). Static bacterial cultures were started from freezer
stocks, grown at 37°C for 18 h, and then subcultured at 1:250 (for UTI89 and
TOP52) or 1:100 (for 0852) into fresh media. These subcultures were then grown
statically at 37°C for 18 h (for UTI89 and TOP52) or 2 to 3 h (for 0852), pelleted,
resuspended in phosphate-buffered saline, and diluted appropriately to yield 50
l inocula (for UTI89 and TOP52) or 200 l inocula (for 0852) of 1 107 to 2
107 CFU unless otherwise indicated. For competition experiments, 107 CFU
each of K. pneumoniae TOP52 and E. coli UTI89 hk::comGFP were inoculated
together in a total volume of 50 l. To quantify bacteria present in mouse organs,
bladders and kidneys were aseptically harvested at the indicated times postin-
fection, homogenized in phosphate-buffered saline, serially diluted, and plated
onto LB plates, brain heart infusion broth plates, or LB-kanamycin (50 g/ml)
and BBL CHROMagar orientation media (BD Diagnostics) for competition
experiments. All studies were approved by the Animal Studies Committee at
Washington University School of Medicine.
Mouse urine collection and analysis. Urine samples were collected from
diabetic and healthy mice by bladder massage over a sterile 1.5-ml Eppendorf
tube prior to bacterial inoculation. Urine samples were analyzed for glucose,
protein, ketones, and specific gravity by use of Multistix Pro 10 LS urine reagent
test strips (Bayer) according to the manufacturer’s instructions.
Histology and electron microscopy. Infected mouse bladders and kidneys were
aseptically removed, fixed in neutral buffered formalin, and paraffin embedded.
Sections were stained with hematoxylin and eosin and examined using an Olym-
pus BX51 light microscope (Olympus America). For transmission electron mi-
croscopy, glutaraldehyde-fixed kidneys were harvested and processed as previ-
ously described (32). Sections were viewed on a JEOL 1200 EX transmission
electron microscope (JEOL USA) at an 80-kV accelerating voltage.
Urine growth curves. Overnight UTI89 and TOP52 shaking LB cultures were
subcultured at 1:100 into filter-sterilized urine specimens from healthy volun-
teers with and without 2% glucose supplementation. Samples were grown with
shaking at 37°C, and optical density at 600 nm (OD600) readings were taken at
various time points. Doubling times (td) were calculated as follows: td ln 2 (t2
t1)/(ln OD2  ln OD1).
Statistical analysis. Competitive indices were calculated as follows: (UTI89
hk::comGFPout/UTI89 hk::comGFPin)/(TOP52out/TOP52in). The Wilcoxon
signed-rank test was used to compare the log of competitive indices to a theo-
retical mean of zero. Continuous variables were compared using the Mann-
Whitney U test since these variables were not normally distributed. Values below
the limit of detection were assigned this minimum value for statistical analyses.
All tests were two tailed, and a P value of less than 0.05 was considered signif-
icant. These analyses were performed using GraphPad Prism (GraphPad soft-
ware, version 4.03). To calculate 50% infective dose (ID50) values, the Reed and
Muench mathematical technique (46) was used and infection was defined as
organs with bacterial titers above the limit of detection (20 CFU) at 72 h
postinfection.
RESULTS
Diabetic mice have increased susceptibility to UPEC infec-
tion and higher bacterial burden than nondiabetics. It is
widely known that diabetics are more susceptible to UTI than
nondiabetics. To determine if STZ-induced diabetic C3H/HeN
mice are more susceptible to UTI than buffer-treated control
mice, various doses of the UPEC cystitis isolate UTI89 were
inoculated by transurethral catheterization. After 72 h of in-
fection, mice were sacrificed and bladder and kidney bacterial
titers were determined (Fig. 1A). Inocula of 107 (P  0.0006),
106 (P  0.0079), 105 (P  0.0173), 104 (P  0.0080), and 103
(P  0.0317) CFU of E. coli UTI89 all resulted in significantly
higher bladder titers in diabetic mice than in buffer-treated
controls. The majority of healthy buffer-treated mice inocu-
lated with 103 or 104 CFU of UTI89 were able to efficiently
clear infection after 72 h; however, almost all diabetic mice had
significant infection even with these relatively low inocula. De-
fining infection as a titer at 72 h greater than 20 CFU (mini-
mum level of detection), the ID50 of E. coli UTI89 was 1.97 
104 CFU in healthy murine bladders and was less than 100
CFU (approximately 68.1) in diabetic bladders. Kidney titers
FIG. 1. Diabetic mice have increased susceptibility to E. coli UTI89
UTI compared to healthy mice. Female C3H/HeN diabetic mice and
buffer-treated control mice were infected with various inocula of
UTI89, a UPEC cystitis isolate. At 72 h postinfection, bladders (A) and
kidneys (B) were harvested and homogenized and CFU were deter-
mined. Titer data are combined from three independent experiments.
Short bars represent geometric means of each group, and dotted lines
represent limits of detection. The symbol ** indicates significant P
values of less than 0.05.
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were also significantly higher in diabetic mice than in buffer-
treated control mice after inoculation with 107 (P  0.0006),
106 (P  0.0079), 105 (P  0.0087), 104 (P  0.0200), and 103
(P  0.0159) CFU of E. coli UTI89 (Fig. 1B). By 72 h after
inoculation with 103 CFU of UTI89, all diabetic mice had
significant kidney titers while only half of the healthy mice
remained infected. The ID50 of UTI89 was 2.08  10
3 CFU in
healthy murine kidneys and was less than 100 CFU (approxi-
mately 46.4) in diabetic kidneys.
The kinetics of urinary tract colonization by E. coli UTI89
were compared between diabetic mice and healthy controls
(Fig. 2A and B). UTI89 efficiently colonized mouse bladders as
early as 6 h postinfection in both healthy and diabetic mice
(Fig. 2A). The bacterial load in infected bladders of healthy
mice decreased to a geometric mean of 9.2  103 CFU per
bladder by 72 h postinfection. Diabetic mouse bladders, on the
other hand, retained high levels of bacterial colonization at
72 h postinfection. Similar patterns of persistent high-level
colonization throughout the course of infection were seen in
infected kidneys of diabetic mice (Fig. 2B).
These data show that diabetic mice are more susceptible to
infection by the UPEC isolate UTI89. UTI89 had a consider-
ably lower ID50 in the diabetic background than in healthy
control mice. UTI89 also had significantly higher bladder titers
at 6, 24, and 72 h postinfection in diabetic mice than in healthy
mice. Additionally, diabetic mice had higher UTI89 titers in
the kidneys than did healthy mice, especially at later time
points in infection.
Diabetic mice infected with K. pneumoniae or E. faecalis have
higher burdens of infection than nondiabetic mice. Diabetics
are more likely to get UTIs caused by non-UPEC uropatho-
gens than are nondiabetic individuals. To determine how non-
UPEC uropathogens perform in the diabetic mouse model
over time, we inoculated diabetic and buffer-treated control
mice with either the K. pneumoniae isolate TOP52 (Fig. 2C and
D) or the E. faecalis isolate 0852 (Fig. 3) in their respective
murine models of UTI. As early as 6 h postinfection, the
bacterial load of K. pneumoniae TOP52 was 100-fold higher in
the bladders of diabetic C3H/HeN mice than in those of
healthy C3H/HeN mice (Fig. 2C) (P 0.0005). This difference
between healthy and diabetic bladder TOP52 bacterial burdens
was further exaggerated to greater than 1,000-fold by 24 h
postinfection (P  0.0007). K. pneumoniae TOP52 showed
similar levels of infection in the kidneys of diabetic and healthy
mice at 6 h, but diabetic bacterial burdens were significantly
higher by 24 h (P  0.0007) and 72 h (P  0.0043) postinfec-
tion.
In the C57BL/6 UTI model, the E. faecalis isolate 0852
showed no difference in bacterial titer at 2 days postinfection in
the bladders (Fig. 3A) and kidneys (Fig. 3B) of diabetic and
control mice. However, diabetic mouse kidneys had signifi-
cantly higher bacterial burdens than buffer-treated control
mouse kidneys at both 7 days (P  0.0229) and 14 days (P 
0.0135) postinfection. E. faecalis 0852 titers were also signifi-
cantly higher in diabetic mouse bladders than in control mouse
bladders at 7 days (P  0.0119) and 14 days (P  0.0420)
postinfection.
These data demonstrate that diabetic mice have greater bur-
dens of UTI caused by the K. pneumoniae isolate TOP52 or the
E. faecalis isolate 0852 than do healthy mice. The experiments
involving E. faecalis in the C57BL/6 background also illustrate
the versatility of STZ induction of diabetes and the ability to
FIG. 2. Time course of E. coli UTI89 and K. pneumoniae TOP52 bladder and kidney infections in healthy and diabetic mice. Female C3H/HeN
diabetic mice (	) and buffer-treated control mice (●) were inoculated with 107 CFU of the UPEC isolate UTI89 (A and B) or with 107 CFU of
the K. pneumoniae isolate TOP52 (C and D) by transurethral catheterization. For organ titers, bladders (A and C) and kidneys (B and D) were
harvested at various time points postinfection and CFU were calculated. Graphs of bacterial burden of E. coli UTI89 in the bladder (A) and kidneys
(B) and K. pneumoniae TOP52 in the bladder (C) and kidneys (D) are shown. Titer data are combined from three independent experiments. Short
bars represent geometric means of each group, and dotted lines represent limits of detection. The symbol ** indicates significant P values of less
than 0.05.
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adapt this method to preexisting models of UTI characterized
for specific uropathogens. Interestingly, the K. pneumoniae
strain TOP52 has even larger differences between bladder bac-
terial loads of diabetic and control mice than does the E. coli
strain UTI89 at 6 and 24 h postinfection. This greater advan-
tage afforded to TOP52 in the diabetic background is consis-
tent with the higher rates of K. pneumoniae cystitis observed in
diabetic patients.
Advantages between UPEC and non-UPEC uropathogens
shift in the diabetic host. To directly compare UPEC to gram-
negative non-UPEC uropathogens in the diabetic model, we
conducted competition experiments in which 107 CFU E. coli
UTI89 hk::comGFP and 107 CFU K. pneumoniae TOP52 were
coinoculated into diabetic and buffer-treated C3H/HeN mice.
UTI89 hk::comGFP has a kanamycin resistance cassette allow-
ing for selection on antibiotic media. After 24 h, bladders and
kidneys were harvested, titers of each pathogen were enumer-
ated, and competitive indices were calculated. We then com-
pared the log competitive indices of healthy and diabetic mice
in the bladder (Fig. 4A) and kidney (Fig. 4B). A value of
greater than zero indicates that UTI89 hk::comGFP outcom-
petes TOP52, while a value of less than zero indicates that
TOP52 outcompetes UTI89 hk::comGFP. In the bladders of
buffer-treated mice, the log of the competitive indices was
significantly greater than zero (P  0.0020), indicating that E.
coli UTI89 hk::comGFP has a significant advantage over K.
pneumoniae TOP52. In diabetic bladders, the log of competi-
tive indices was also significantly greater than zero (P 
0.0371), albeit to a lesser degree than in healthy bladders.
Thus, the competitive advantage of UTI89 hk::comGFP over
TOP52 seems more pronounced in healthy bladders than in
diabetic bladders. In the kidney, while K. pneumoniae TOP52
had a significant advantage over E. coli UTI89 hk::comGFP in
the healthy background (P  0.0137), UTI89 hk::comGFP
substantially outcompeted TOP52 in the diabetic host (P 
0.0200).
An increased prevalence of non-UPEC strains causes cystitis
in diabetic patients. In our model, the diabetic condition gave
E. coli a lesser advantage over K. pneumoniae in the bladder,
consistent with the increased prevalence of K. pneumoniae
cystitis in diabetics. In the kidney, the situation was different.
We found a dramatic shift in the kidney from an environment
favoring K. pneumoniae in control mice to an environment
favoring UPEC colonization in the diabetic setting.
UPEC causes marked interstitial pyelonephritis in diabetic
mice. To further investigate the shift favoring an E. coli UTI89
competitive advantage in the diabetic kidney, we examined
histologic hematoxylin and eosin-stained sections of single 72-h
infections of E. coli UTI89 or K. pneumoniae TOP52. The renal
pelvises (Fig. 5A) of buffer-treated control mice inoculated
with UTI89 or TOP52 showed low levels of inflammation. The
pelvises of infected diabetic mice infected with UTI89 or
TOP52 were dilated and significantly inflamed, often with large
sheets of PMN. The urothelium lining the pelvis was hyper-
plastic, with intraurothelial neutrophilia, and collections of
bacteria were observed within the pelvic space. The kidney
parenchyma (Fig. 5B) of healthy control mice infected with
FIG. 3. Time course of E. faecalis 0852 bladder and kidney infec-
tions in healthy and diabetic mice. Female C57BL/6 diabetic mice (	)
and buffer-treated control mice (●) were inoculated with 107 CFU of
the Enterococcus faecalis isolate 0852 by transurethral catheterization.
Bladders and kidneys were harvested at various time points postinfec-
tion, and CFU were calculated. Graphs of bacterial burden of E.
faecalis 0852 in the bladder (A) and in the kidneys (B) are shown. Titer
data are combined from two independent experiments. Short bars
represent geometric means of each group, and dotted lines represent
limits of detection. The symbol ** indicates significant P values of less
than 0.05. d, days.
FIG. 4. Competition of E. coli UTI89 and K. pneumoniae TOP52 in
the bladders and kidneys of healthy and diabetic mice. Female C3H/HeN
diabetic mice (	) and buffer-treated control mice (●) were infected with
107 CFU each of E. coli UTI89 hk::comGFP and K. pneumoniae TOP52.
After 24 h, bladders (A) and kidneys (B) were harvested, CFU of
each pathogen were enumerated, and competitive indices [(UTI89
hk::comGFPout/UTI89 hk::comGFPin)/(TOP52out/TOP52in)] were calcu-
lated. A value of greater than zero indicates anE. coliUTI89 hk::comGFP
advantage, while a value of less than zero indicates a K. pneumoniae
TOP52 advantage. The logs of the competitive indices were significantly
different than zero in all cases. Data are combined from two independent
experiments. Bars represent means of each group, and dotted lines rep-
resent values at which each uropathogen competes equally.
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TOP52 or UTI89 and of diabetic TOP52-infected mice were
largely unremarkable, with patent tubules and normal-appear-
ing glomeruli. In contrast, the diabetic E. coli UTI89-infected
kidney parenchyma displayed marked acute interstitial pyelo-
nephritis with cortical and medullary involvement. There were
multiple areas of abscessation, with widespread destruction of
renal architecture. High-power views of these regions (Fig. 5C
and D) showed marked inflammation that was largely neutro-
philic in nature, with a small component of lymphocytes and
plasma cells. Vast collections of extracellular bacteria filled the
lumina of renal tubules. Intratubular and peritubular PMN
were also observed.
To further characterize the collections of bacteria observed
within the kidney tubules, transmission electron microscopy
was performed (Fig. 5E and F). Bacteria were tightly packed
between simple tubular epithelial cells of the kidney. An ex-
tracellular-matrix material was observed between bacteria.
These UPEC collections had morphology and spacing similar
to those of the intracellular bacterial communities formed in
the bladder during cystitis.
Bladder histologies were similar between E. coli UTI89-
infected and K. pneumoniae TOP52-infected bladders. In the
healthy mouse bladders at 72 h, moderate acute inflammation
and epithelial hyperplasia were observed. Diabetic mouse
bladders had increased luminal bacteria and PMN compared
to levels for buffer-treated controls (data not shown).
These findings demonstrate a significant pyelonephritic phe-
notype in the kidneys of UPEC-infected diabetic mice. This
phenotype is specific to E. coli UTI89, as it was not observed
for K. pneumoniae TOP52-infected diabetic kidneys, and is
consistent with the significant advantage of UTI89 over TOP52
in the diabetic kidney.
Diabetes in TLR-4-deficient mice. Many studies have argued
that diabetics have a defect in host inflammatory cell function
which may contribute to their increased infection rate. To
further investigate whether innate host immunity or other fac-
FIG. 5. E. coli UTI89 causes acute interstitial pyelonephritis in the kidneys of diabetic mice. Kidney sections from 72 h after infection with E.
coli UTI89 or K. pneumoniae TOP52 were analyzed by light microscopy. (A) Renal pelvises from diabetic mice infected with either UTI89 or
TOP52 revealed increased inflammatory cells, primarily PMN. (B) The kidney parenchyma appeared largely normal in healthy mice and in diabetic
mice infected with TOP52; however, UTI89-infected kidneys showed marked histopathology with a loss of tissue architecture and a significant
inflammatory infiltrate. (C and D) High-power magnification of UTI89-infected kidneys revealed large collections of bacteria filling the renal
tubule lumina and collections of intratubular and peritubular PMN. (E and F) Electron microscopy of these renal tubules showed a tight collection
of bacteria embedded in an extracellular-matrix material. Bars, 100 m (A and B), 50 m (C and D), 1 m (E), and 0.2 m (F).
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tors irrespective of innate immunity play roles in the differ-
ences observed between diabetic and healthy infections, we
inoculated diabetic and healthy C3H/HeJ and C3H/HeN fe-
male mice with E. coli UTI89 or K. pneumoniae TOP52 (Fig.
6). C3H/HeJ mice contain a mutation in the Toll-like receptor
4 (TLR-4) signaling domain and thus fail to transmit a signal.
It has been shown that UPEC colonizes the bladders and
kidneys of C3H/HeJ mice to significantly higher levels than
those of C3H/HeN mice without inducing a significant neutro-
phil response early in infection (18, 50). Diabetic C3H/HeJ
mice were more prone to infection by E. coli UTI89 at 72 h
postinfection than healthy controls (Fig. 6A) (P 0.0221). The
presence of a diabetic advantage in C3H/HeJ mice suggests
that additional TLR-4-independent factors may be important
in diabetic UTI. However, the difference in UTI89 titers be-
tween healthy and diabetic bladders was greater in C3H/HeN
mice (10,000-fold increase) than in C3H/HeJ mice (100-fold
increase), suggesting that innate immune factors related to
TLR-4-regulated processes may also be important. UTI89 had
less than a 10-fold advantage in diabetic kidneys of C3H/HeJ
mice (Fig. 6B) (P  0.0023) at 72 h postinfection than in
healthy controls, compared to the 10,000-fold advantage seen
for C3H/HeN kidneys. Thus, TLR-4-regulated factors may ac-
count for much of the increase in bacterial burdens in diabetic
mouse kidneys compared to those in healthy controls.
K. pneumoniae TOP52 had significantly higher titers in the
bladders (Fig. 6C) of diabetic C3H/HeN (P  0.0043) and
C3H/HeJ (P  0.0043) mice than in those of buffer-treated
controls. Interestingly, the differences in geometric means of
the 72-h-titer data were roughly equivalent in the C3H/HeN
and C3H/HeJ backgrounds. Similarly to results for UTI89,
while TOP52 displayed a significant advantage in the kidneys
(Fig. 6D) of diabetic C3H/HeN mice compared to those of
healthy C3H/HeN controls (P  0.0043), TOP52 had no ad-
vantage in the kidneys of diabetic C3H/HeJ mice compared to
those of healthy C3H/HeJ controls (P  0.9307). Thus, TLR-
4-regulated factors seemingly account for much of the in-
creased advantage of TOP52 in the C3H/HeN kidney. Induc-
ing diabetes in the C3H/HeJ mice produced no additional
observable effects. Thus, much of the increase in C3H/HeN
kidney colonization conferred upon inducing diabetes may be
due to certain defects in TLR-4-regulated innate immune fac-
tors, although non-TLR-4-related factors may also be impor-
tant.
Taken together, these experiments suggest that the diabetic
phenotypes observed for both UPEC and non-UPEC organ-
isms are likely multifactorial. A defect in TLR-4-regulated
factors may play a role for diabetic mice. Nevertheless, other
diabetic effects, irrespective of TLR-4, are also important in
the ability of uropathogens to cause high burdens of infection
in the urinary tract.
Urine growth curves. Poorly regulated diabetic patients of-
ten spill glucose into their urine. To determine whether STZ-
treated diabetic mice have glucosuria, we collected urine sam-
ples from diabetic and buffer-treated control mice. Urine test
reagent strips were used to determine the glucose status and
specific gravity of the mouse urine prior to inoculation with a
uropathogen. Diabetic mouse urine consistently had 200
mg/dl (2%) glucose and a low specific gravity of 1.010. Healthy
control mouse urine was negative for glucose and had a specific
gravity of 1.030. Similar trace amounts of protein and ketones
were found in diabetic and healthy mouse urine.
E. coli UTI89 and K. pneumoniae TOP52 grow equally well
in LB, with doubling times of 34 min (Fig. 7A). To determine
FIG. 6. Differences in diabetic UTI in C3H/HeN and C3H/HeJ mice. Female C3H/HeN and C3H/HeJ diabetic mice (	) and buffer-treated
control mice (●) were inoculated with 107 CFU of E. coli UTI89 (A and B) or 107 CFU of K. pneumoniae TOP52 (C and D). For organ titers,
bladders (A and C) and kidneys (B and D) were harvested at 72 h postinfection and CFU were calculated. Graphs of bacterial burden of UTI89
in the bladders (A) and kidneys (B) and TOP52 in the bladders (C) and kidneys (D) of both mouse backgrounds are shown. Titer data are
combined from two independent experiments. Short bars represent geometric means of each group, and dotted lines represent limits of detection.
The symbol ** indicates significant P values of less than 0.05.




arch 18, 2014 by W







whether the glucosuria of the diabetic mice affects uropatho-
gen growth, E. coli UTI89 and K. pneumoniae TOP52 were
grown in filter-sterilized urine from healthy human subjects
with and without 2% glucose supplementation (Fig. 7B). Op-
tical density readings of both UTI89 and TOP52 correlated
with CFU during logarithmic growth. The doubling times of
both UTI89 (1.36 h with glucose and 2.24 without glucose, P 
0.0379) and TOP52 (1.05 h with glucose and 1.87 without
glucose, P  0.0262) were significantly shorter in glucose-
supplemented urine. TOP52 displayed higher yields than
UTI89 in urine with (P  0.0286) and without (P  0.0286)
glucose supplementation.
These data show that STZ-induced diabetic mice have glu-
cosuria similar to that of poorly controlled diabetics. This urine
glucose may contribute to the increased bacterial burden
within the urinary tracts of diabetic mice.
DISCUSSION
Models of STZ-induced diabetes have been used for de-
cades (8, 28, 31); however, little has been done to study dia-
betic UTI. UTIs are more prevalent and more severe in the
diabetic population than in the nondiabetic population, and
murine models of infection that accurately mirror human in-
fection are required to better understand disease (42). STZ-
induced diabetic mice were more susceptible to UPEC UTI
and had higher burdens of infection than buffer-treated con-
trols. Remarkably low inocula of the UPEC strain UTI89 were
able to effectively infect diabetic mice but were largely cleared
from healthy mice. It is also known that diabetic patients are
more likely to be infected with non-UPEC uropathogens (29).
The K. pneumoniae strain TOP52 and the E. faecalis strain
0852 had significantly higher bacterial titers in the bladders and
kidneys of STZ-induced diabetic mice than in those of healthy
mice. E. coli UTI89 outcompeted K. pneumoniae TOP52 in
both healthy and diabetic bladders. However, the advantage of
UTI89 over TOP52 in the bladders of diabetic mice was re-
duced. This result reflects the clinical diabetic situation in
which UPEC remains the predominant uropathogen, with an
increased frequency of K. pneumoniae infection. In contrast,
the advantage of UTI89 in the kidneys of diabetic mice over
TOP52 was dramatic, since TOP52 outcompeted UTI89 in
healthy kidneys. Finally, experiments with C3H/HeJ mice sug-
gested that defects in the diabetic urinary tract to manage and
clear bacterial infection are likely multifactorial, possibly in-
volving TLR-4-regulated factors, glucosuria, and other un-
known factors. All of these findings are consistent with human
diabetic UTI epidemiologic data and suggest that this STZ-
induced model of diabetic UTI can provide a valuable tool for
studying this disease.
Histologic analysis of mouse kidneys revealed a severe pyelo-
nephritic phenotype specific to E. coli UTI89 in the diabetic
setting. Large extracellular bacterial biofilm-like communities
were observed filling renal tubules. Bacteria within these com-
munities were tightly packed within an extracellular matrix.
Morphologically, these bacterial collections appeared similar
to the UPEC biofilm-like intracellular bacterial communities
observed within facet cells of the bladder (1, 48). Further
studies are required to determine what enables UTI89 to form
these communities within the renal tubules of the diabetic host.
There are numerous hypotheses for the enhanced ability of
uropathogens to infect the urinary tracts of diabetic individuals
(12). Poorly controlled diabetes often results in the spilling of
glucose into the urine. Glucosuria increased the growth rates
of UTI89 and TOP52 and has been shown to increase growth
of numerous other uropathogenic isolates (10). Multiple stud-
ies have suggested that neutrophil dysfunction and differences
in cytokine secretion may play important roles in diabetic UTI
(11, 43, 52); however, data contradicting these claims have also
been reported (3). We discovered that diabetes in C3H/HeJ
mice resulted in significantly increased colonization of the
bladders and kidneys by E. coli, albeit the effect was decreased
compared to that in C3H/HeN mice. Additionally, the induc-
tion of diabetes resulted in no advantage for K. pneumoniae in
the diabetic kidneys of C3H/HeJ mice. These results argue that
both TLR-4-related and -unrelated factors may be defective in
the setting of diabetes. TLR-4-regulated factors affected by
diabetes may include the inability of neutrophils to effectively
clear bacteria, as was seemingly the case for the diabetic kid-
neys infected by E. coli UTI89. UTI89 was able to establish
massive extracellular biofilm-like collections even in the pres-
ence of a robust neutrophilic inflammatory infiltrate. Finally,
studies have suggested that bacteria have increased adherence
abilities in the urinary tracts of diabetics, possibly due to lower
levels of urine Tamm-Horsfall protein in diabetics (4, 7, 45) or
potential changes in the uroepithelial cells themselves (13).
This murine model of diabetic UTI provides a powerful tool
for dissecting these and other factors involved in diabetic uro-
pathogenesis.
The STZ-induced diabetic UTI mouse model is extremely
versatile. A type 1 diabetic syndrome can be induced in differ-
ent murine backgrounds, allowing for the analysis of specific
host factors in knockout or mutant mouse backgrounds. Ad-
FIG. 7. Addition of glucose enhances E. coli UTI89 and K. pneu-
moniae TOP52 growth in urine. Growth of E. coli UTI89 and K.
pneumoniae TOP52 over time was measured in LB (A) and filter-
sterilized urine with and without the supplementation of 2% glucose
(B). Growth curves shown are representative of three independent
experiments.
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ditionally, uropathogens have been studied with various mouse
strains and this method of STZ induction can be applied to the
mouse strain best characterized for a given uropathogen. For
example, we were able to induce diabetes and analyze infection
by using the previously established mouse model of E. faecalis
UTI in the C57BL/6 murine background (25). The STZ
method of diabetic induction is extremely practical, with high
levels of penetrance (80 to 85%) in a relatively short period of
time (2 to 3 weeks), and can be well controlled with buffer i.p.
injections in the identical mouse strain. While STZ produces a
type-1-like, irreversible insult to pancreatic -cells, leading to a
severe diabetic phenotype in these mice (8), it may be possible
to treat these mice with insulin or other agents to contrast UTI
in the settings of controlled and uncontrolled diabetes. It is
currently unclear whether the diabetic UTI phenotypes ob-
served will be present in a euglycemic diabetic host. Addition-
ally, this model could be used to test various UTI preventative
measures, including vaccinations, which may be especially ben-
eficial for this predisposed population.
This STZ-induced murine model of diabetic UTI is consis-
tent with many known characteristics of human diabetic UTI,
including increased susceptibility to infection and more-severe
infection. Many of these traits of diabetic UTI are poorly
understood and require an infection model to test hypotheses
of diabetic uropathogenesis. Using this model, we discovered
that diabetes affects E. coli, K. pneumoniae, and E. faecalis
pathogenesis in diverse ways. Defects in TLR-4-dependent and
-independent pathways appear to provide differential advan-
tages to these pathogens. A dramatic decrease in the ID50 may
explain the increased susceptibility of diabetics in general, and
the ability of E. coli to establish biofilms in the diabetic kidney
provides insights into the increased virulence seen in diabetics.
This model of diabetic UTI is versatile and practical and can
provide a powerful tool for dissecting UTI in the setting of
diabetes.
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